Comparative Pharmacology
Head-to-head clinical analysis: DASETTA 1 35 versus NORLESTRIN 21 2 5 50.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DASETTA 1 35 versus NORLESTRIN 21 2 5 50.
DASETTA 1/35 vs NORLESTRIN 21 2.5/50
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Combination of an estrogen (ethinyl estradiol) and a progestin (norethindrone). Suppresses gonadotropin-releasing hormone (GnRH) from the hypothalamus, reducing luteinizing hormone (LH) and follicle-stimulating hormone (FSH) secretion from the pituitary, thereby inhibiting ovulation. Additionally, induces changes in cervical mucus (impenetrability to sperm) and endometrium (reduced likelihood of implantation).
Combination oral contraceptive containing an estrogen (ethinyl estradiol) and a progestin (norethindrone acetate). Inhibits ovulation by suppressing gonadotropin release. Increases viscosity of cervical mucus, impeding sperm penetration, and alters endometrial receptivity.
One tablet orally once daily, each containing 1 mg norethindrone acetate and 35 mcg ethinyl estradiol.
One tablet orally once daily for 21 days, followed by 7 days off, then repeat.
None Documented
None Documented
Norethindrone: 5-14 hours (mean 8 hours); ethinyl estradiol: 10-20 hours (mean 14 hours). Clinical context: steady-state achieved within 5-7 days.
Norethindrone: 8 hours (terminal); Ethinyl estradiol: 13 hours (terminal). Clinical context: Steady-state achieved after 3-5 days; dosing interval based on once-daily administration.
Renal (55-60% as metabolites, 25-30% as unchanged drug and conjugates), biliary/fecal (30-35% as metabolites).
Renal: 50-60% as metabolites (glucuronide and sulfate conjugates of norethindrone and ethinyl estradiol); fecal: 30-40% via biliary elimination; <1% unchanged.
Category C
Category C
Oral Contraceptive
Oral Contraceptive